JD Health International (6618) Fundamentals 2026 — P/E 19.4x, Revenue Analysis | SniperIQ
JD Health International (6618) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of HK
7.68 on the HKSE. This SniperIQ fundamentals page covers JD Health International's valuation (P/E 19.4x, P/B 1.7x), profitability (net margin 7.3%), revenue (¥73.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JD Health International's market cap?
JD Health International (6618) has a market capitalization of approximately HK
7.68 on the HKSE. Market cap moves with the live share price.What is JD Health International's P/E ratio?
JD Health International's trailing twelve-month P/E ratio is 19.4x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JD Health International?
JD Health International runs a net profit margin of 7.3%, a gross margin of 24.8%, and an operating margin of 5.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JD Health International generate?
JD Health International reported revenue of ¥73.4B for fiscal year 2025, with net income of ¥5.4B and earnings per share (EPS) of 1.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JD Health International pay a dividend?
JD Health International does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is JD Health International financially healthy?
JD Health International carries a debt-to-equity ratio of 0.01x and a current ratio of 2.72x, with a market beta of 1.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JD Health International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JD Health International (6618) the key facts are: market cap HK
Track JD Health International's full fundamentals live
Get JD Health International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.